|
Stryker Orthopaedics enters into agreement with OrthoSensor for intelligent surgical platform
Stryker Corporation’s Orthopaedics Division and OrthoSensor, Inc., the leader in intelligent orthopaedics, today announced an agreement in which OrthoSensor will provide the OrthoSensor™ Knee Trial, designed for use with Stryker’s Triathlon Knee System. The OrthoSensor Knee Trial is an intelligent trial that provides quantitative, intra-operative feedback to surgeons to optimise joint balance during total knee arthroplasty.
The OrthoSensor Knee Trial has embedded micro-electronics and sensors in single-use trial inserts, delivering data to optimise the final ligament balance and patients’ specific joint kinematics. The sensor wirelessly transmits this key information to a graphic display of real-time feedback, enabling the surgeon to visualise and quantify joint loading and balance. With this evidence, the surgeon can make an informed choice to modify implant positioning, adjust leg alignment and optimise soft tissue balance through a full range of motion.
“The single radius design philosophy of Stryker knees is a perfect complement to OrthoSensor’s innovative technology,” said Doug Leach, vice president of global research and development, knee reconstruction at Stryker Orthopaedics. “The Triathlon Knee System is uniquely suited to the finer elements of ligament balancing and being able to take advantage of this new offering provides us with the opportunity to combine our advanced orthopaedic implant technology with cutting-edge sensor technology.”
Stryker’s Triathlon Knee System offers patients the potential for improved motion and better fit, and remains classified as the knee system that outperforms the most frequently used brands in terms of revision rates as identified in the National Joint Registry of England and Wales.
“By integrating sensors into the surgical suite, OrthoSensor is leading the evolution in intelligent orthopaedic surgery and we are pleased to collaborate with Stryker Orthopaedics to turn this new field into a reality,” said Jay Pierce, CEO of OrthoSensor. “Until now, surgeons have lacked quantifiable data about joint kinematics and their decisions varied based on individual judgment, experience and skill set. OrthoSensor’s intelligent surgical systems will provide surgeons, hospitals and health plans access to real-time data to improve patient care, measure clinical outcomes and lower costs related to treating musculoskeletal disease.”
SANUWAVE Health granted U.S. Patent on use of acoustic shock waves to treat orthopaedic conditions
SANUWAVE Health, Inc., an emerging medical technology company focused on the development and commercialisation of noninvasive, biological response activating devices in regenerative medicine, today announced that the United States Patent and Trademark Office issued U.S. patent 7,985,189 entitled “Method For Using Acoustic Shock Waves in the Treatment of Medical Conditions” to the company.
The patent covers the treatment of a variety of orthopaedic conditions, such as tendinitis (chronic joint inflammation and pain), osteoporosis (brittle bones with an increased risk of fracture) and actual bone stress fracture healing. Treatments are characterised as acoustic shock wave applications, that under the patented treatment times and energy dosages, cause the stimulation of growth factors and a resulting increase in new blood vessel formation to promote or accelerate the body’s natural healing processes and responses, thereby inducing or accelerating healing.
Christopher M. Cashman, President and CEO of SANUWAVE, said, “The issuance of this patent provides strong and broad intellectual property protection for PACE® (Pulsed Acoustic Cellular Expression) technology in a variety of musculoskeletal indications whose combined market potential exceeds $1 billion in the U.S. alone. This is particularly important as we begin to execute our regulatory strategy for orthoPACE® in the U.S. In addition, it strengthens the patent portfolio we are building around our proprietary form of extracorporeal shock wave technology (ESWT) called PACE technology and provides significant barriers to entry for any would-be competitors.”
Orthopaedic, sports medicine and trauma conditions treated with PACE, including tendinitis, osteoporosis and bone healing, have documented success rates that are equal to and often greater than that of surgery – usually with just one procedure and without the inherent risks, complications and lengthy recovery time associated with invasive surgery. Most procedures can be performed in less than 15 minutes, and patients can return home the same day. Patients can usually bear weight immediately and are able to return to normal activity within a few days of the procedure. PACE procedures are completely noninvasive so there is no risk of infection or scarring, and more importantly, PACE treatment preserves the opportunity for future treatment options, as it does not change the biomechanics of the underlying musculoskeletal system.
|
